Celmatix
Adrienne Day, Ph.D. has more than 30 years of business development experience in the biotechnology and biopharmaceutical industries. She was most recently Senior Director of Business Development for Ferring Pharmaceuticals, where she launched technology access and research collaborations, identified and championed the acquisition of microbiome replacement therapy, and managed global academic collaborations with more than 60 academic institutions. Prior to her role at Ferring, Adrienne ran consulting practice providing transaction and strategic support to venture capital, biotechnology, and biopharmaceutical organizations. She has previously served as Vice President of Business Development at what is now the Sanford Burnham Prebys Medical Discovery Institute, Vice President of Business Development at Conforma Therapeutics, Senior Director of Business Development at Molecumetics Ltd., and Associate Director of Corporate Development at Ligand Pharmaceuticals.
This person is not in any teams
This person is not in any offices
Celmatix
Celmatix Inc. is a preclinical-stage women’s health biotech focused uniquely on ovarian biology. With a lead “pipeline-in-a-pill” AMHR2 program focused on ovarian senescence, and collaborations in PCOS and non-hormonal contraception with industry leaders, Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health.